ANT2681 is a novel and potent metallo ß-lactamase (MBL) inhibitor that displays excellent activity against New Delhi Metallo ß-lactamase (NDM) carrying carbapenem-resistant Enterobacterales (CRE). It will be administered intravenously in conjunction with meropenem for the treatment of NDM-CRE, which are prevalent throughout China and the Asia Pacific region and for which no inhibitors are currently available. ANT2681 has received QIDP status from the FDA for complicated urinary tract infections (cUTI).